Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|July 4, 2025
Q2 2025 Recap: Cardiology News and Updates
Author(s)Patrick Campbell
Fact checked by: Abigail Brooks, MA
Our recap of Q2 2025 in cardiology spotlights 3 FDA headlines, trial news, and new episodes of Don't Miss a Beat.
Advertisement
Advertisement
The second quarter of 2025 brought a steady stream of momentum in cardiology, with developments spanning early-stage innovation, late-phase trial results, and new FDA approvals. This quarter’s recap includes 3 key regulatory milestones—including a major hypertension approval and a fast-tracked gene editing therapy—as well as 3 headline-making trial readouts that challenged, confirmed, or extended the evidence base in high-risk populations.
Related to this article
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Advertisement
Advertisement